Skip to content
PodParley
Pareto Securities Healthcare Conference: BioInvent believes that it has found the next big checkpoint in TNFR2 - this summer they had data both in solid and liquid tumors episode artwork

EPISODE · Sep 2, 2026 · 7 MIN

Pareto Securities Healthcare Conference: BioInvent believes that it has found the next big checkpoint in TNFR2 - this summer they had data both in solid and liquid tumors

from BiotechTV - News · host BiotechTV

CEO Martin Welschof walks us through recent ASCO (ovarian in combo with Keytruda) and EHA (CTLC) data for BI-1808, and describes why the company believes TNFR2 is a compelling checkpoint with wide applicability. Plus, BI-1206 (FcyRIIB), which will have NCSLC data later this year and BioInvent ultimately hopes to partner.

Episode metadata supplied by the publisher feed · Published Sep 2, 2026

Embed this episode

Ready to play

Pareto Securities Healthcare Conference: BioInvent believes that it has found the next big checkpoint in TNFR2 - this summer they had data both in solid and liquid tumors

0:00 7:34

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 7 minutes long.

When was this BiotechTV - News episode published?

This episode was published on September 2, 2026.

Can I download this BiotechTV - News episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!